Henry Schein stock (US42548G1040): Q1 earnings beat and 2026 guidance lift

Henry Schein reported Q1 2026 results on May 5, topping EPS and revenue estimates while updating full-year guidance. The latest move also follows an intraday stock gain and keeps the dental distribution name in focus for U.S. investors.

Henry Schein reported first-quarter 2026 results on May 5, 2026, with adjusted EPS of $1.32 versus the $1.20 consensus estimate and revenue of $3.37 billion, above expectations, according to Henry Schein Investor Relations as of 05/05/2026 and MarketBeat as of 05/05/2026. The stock remained on watch for U.S. retail investors because Henry Schein is listed on Nasdaq and serves dental and medical customers across North America and beyond.

As part of the same update, management lifted full-year 2026 revenue guidance to $13.6 billion-$13.8 billion and EPS guidance to $5.23-$5.37, which framed the quarter as a cleaner visibility update rather than just a one-off beat, according to MarketBeat as of 05/05/2026. The shares also traded higher on May 14, 2026, with one market snapshot showing an intraday gain of 4.5% to $72.61, adding a near-term price catalyst to the earnings story.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Henry Schein
• Sector/industry: Healthcare distribution and dental technology
• Headquarters/country: United States
• Core markets: Dental and medical products, with meaningful exposure to the U.S. healthcare market
• Home exchange/listing venue: Nasdaq (HSIC)
• Trading currency: U.S. dollars

Henry Schein: core business model

Henry Schein sells dental and medical supplies, equipment, and related solutions to clinics, practices, and other care providers. The company’s model combines distribution with technology and services, which gives it more than one revenue stream and ties performance to both healthcare purchasing cycles and practice software demand.

For U.S. investors, that mix matters because the company sits at the intersection of defensive healthcare spending and cyclical capital equipment upgrades. The May 5 earnings release showed that demand trends in the quarter were strong enough to support both a sales beat and a full-year outlook update, according to the company’s filing and earnings summary.

Main revenue and product drivers for Henry Schein

Dental products remain the core driver, but the company also benefits from equipment, technology, and value-added services that can lift average order size and customer stickiness. That matters in a market where offices want broader vendor relationships and software-linked workflows rather than simple commodity supply orders.

Management’s updated 2026 revenue range of $13.6 billion to $13.8 billion suggests that the business entered the second quarter with enough visibility to keep the top line moving in a relatively stable band, according to the May 5 update summarized by MarketBeat as of 05/05/2026. The Q1 result also showed that earnings power is still closely tied to execution on margins and mix.

Why Henry Schein matters for U.S. investors

The stock is relevant to U.S. investors because it is a Nasdaq-listed healthcare distributor with direct exposure to American dental offices, a large installed base, and ongoing technology adoption. That makes it a practical way to track both healthcare utilization and spending patterns in a niche but essential segment.

The latest earnings report also gives investors a fresh read on whether the company can keep converting revenue growth into earnings growth. With the shares moving higher on the May 14 snapshot and valuation screens placing the stock around $72.61, Henry Schein remains tied to both operating performance and market sentiment.

Conclusion

Henry Schein’s latest catalyst is the May 5 Q1 2026 report, which paired an earnings beat with revenue above estimates and a higher full-year outlook. That combination is usually more durable than a single headline surprise because it points to both current-quarter execution and management confidence about the rest of the year. For investors following U.S. healthcare distribution, the stock now sits at the intersection of earnings momentum, guidance, and broader demand trends in dental care.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.